Biochemical markers predicting survival in peroxisome biogenesis disorders.
OBJECTIVE
To identify prognostic markers reflecting the extent of peroxisome dysfunction in primary skin fibroblasts from patients with peroxisome biogenesis disorders (PBD).


BACKGROUND
PBD are a genetically heterogeneous group of disorders due to defects in at least 11 distinct genes. Zellweger syndrome is the prototype of this group of disorders, with neonatal adrenoleukodystrophy and infantile Refsum disease as milder variants. Common to these three disorders are liver disease, variable neurodevelopmental delay, retinopathy, and perceptive deafness. Because genotype-phenotype studies are complicated by the genetic heterogeneity among patients with PBD, the authors evaluated a series of biochemical markers as a measure of peroxisome dysfunction in skin fibroblasts.


METHODS
Multiple peroxisomal functions including de novo plasmalogen synthesis, dihydroxyacetonephosphate acyltransferase (DHAPAT) activity, C26:0/C22:0 ratio, C26:0 and pristanic acid beta-oxidation, and phytanic acid alpha-oxidation were analyzed in fibroblasts from a series of patients with defined clinical phenotypes.


RESULTS
A poor correlation with age at death was found for de novo plasmalogen synthesis, C26:0/C22:0 ratio, and phytanic acid alpha-oxidation. A fairly good correlation was found for pristanic acid beta-oxidation, but the best correlation was found for DHAPAT activity and C26:0 beta-oxidation. A mathematic combination of DHAPAT activity and C26:0 beta-oxidation showed an even better correlation.


CONCLUSIONS
DHAPAT activity and C26:0 beta-oxidation are the best markers in predicting life expectancy of patients with PBD. Combination of both markers gives an even better prediction. These results contribute to the management of patients with PBD.
Gootjes
J
J
Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, The Netherlands.
Mooijer
P A W
PA
Dekker
C
C
Barth
P G
PG
Poll-The
B T
BT
Waterham
H R
HR
Wanders
R J A
RJ
D000217:Acyltransferases / Q000096:biosynthesis / Q000235:genetics; D015415:Biomarkers; D005227:Fatty Acids / Q000378:metabolism; D005347:Fibroblasts; D006801:Humans; D010084:Oxidation-Reduction; D018901:Peroxisomal Disorders / Q000175:diagnosis* / Q000235:genetics / Q000401:mortality*; D020675:Peroxisomes / Q000378:metabolism; D010641:Phenotype; D010831:Phytanic Acid / Q000378:metabolism; D010955:Plasmalogens / Q000096:biosynthesis; D011237:Predictive Value of Tests; D011379:Prognosis; D012189:Retrospective Studies; D013534:Survival; D015211:Zellweger Syndrome / Q000175:diagnosis / Q000235:genetics / Q000401:mortality
D015415:Biomarkers; D005227:Fatty Acids; D010955:Plasmalogens; D010831:Phytanic Acid; C002844:pristanic acid; D000217:Acyltransferases; C020051:glycerone-phosphate O-acyltransferase